You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 42 No. 1, January 1985 TABLE OF CONTENTS
  Archives
  •  Online Features
  CONFERENCE REPORT
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Citing articles on Web of Science (9)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Clinical Impact of Recombinant DNA Research on Neurogenetic Diseases

Report of Mary Jennifer Selznick Workshop, Organized by the Hereditary Disease Foundation

Roger Kurlan, MD

Arch Neurol. 1985;42(1):82-84.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The objective of this workshop was to examine the potential clinical impact of recent developments in DNA technology on neurogenetic diseases, with particular emphasis on Huntington's disease (HD). Ira Shoulson, MD, introduced the workshop by reviewing the clinical characteristics of HD, which include movement disorder (usually chorea), dementia, and psychiatric disturbances. He empha

For editorial comment see p 20.

sized that the diagnosis of HD is based strongly on its hereditary features, which are as follows: autosomal-dominant pattern, complete penetrance, and negligible mutation rate. Because the onset of HD is usually delayed until the third to fifth decades, most persons have children before realizing that they have inherited the disease. There has been no reliable method for a prenatal or presymptomatic diagnosis of HD, and there is no effective therapy.

A number of investigations that used classic polymorphic antigen and enzyme markers to identify a linked marker to the HD . . . [Full Text PDF of this Article]


Author Affiliations

From the Department of Neurology, University of Rochester Medical Center, Rochester, NY.


Footnotes

Accepted for publication April 29, 1984.

Reprint requests to Department of Neurology, University of Rochester, Strong Memorial Hospital, Rochester, NY 14642 (Dr Kurlan).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1985 American Medical Association. All Rights Reserved.